Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial.
Vaccines (Basel)
; 10(11)2022 Nov 04.
Article
in En
| MEDLINE
| ID: mdl-36366373
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Etiology_studies
Language:
En
Journal:
Vaccines (Basel)
Year:
2022
Document type:
Article